Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
BSX 
Boston Scientific Corp (BSX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: BSX (5-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Outstanding Performance
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit 65.22% | Avg. Invested days 80 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 149.74B USD | Price to earnings Ratio 80.99 | 1Y Target Price 115.53 |
Price to earnings Ratio 80.99 | 1Y Target Price 115.53 | ||
Volume (30-day avg) 8115486 | Beta 0.77 | 52 Weeks Range 66.80 - 107.17 | Updated Date 04/1/2025 |
52 Weeks Range 66.80 - 107.17 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 1.25 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 11.07% | Operating Margin (TTM) 17.32% |
Management Effectiveness
Return on Assets (TTM) 5.04% | Return on Equity (TTM) 8.89% |
Valuation
Trailing PE 80.99 | Forward PE 35.46 | Enterprise Value 160474066643 | Price to Sales(TTM) 8.94 |
Enterprise Value 160474066643 | Price to Sales(TTM) 8.94 | ||
Enterprise Value to Revenue 9.58 | Enterprise Value to EBITDA 41.62 | Shares Outstanding 1479069952 | Shares Floating 1471409801 |
Shares Outstanding 1479069952 | Shares Floating 1471409801 | ||
Percent Insiders 0.19 | Percent Institutions 92.99 |
Analyst Ratings
Rating 4.47 | Target Price 99.42 | Buy 8 | Strong Buy 21 |
Buy 8 | Strong Buy 21 | ||
Hold 5 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Boston Scientific Corp
Company Overview
History and Background
Boston Scientific Corp. was founded in 1979. Initially focused on developing less-invasive medical devices, it grew through acquisitions and product innovation, becoming a leader in interventional medical specialties.
Core Business Areas
- MedSurg: Focuses on endoscopy and urology products, including devices for gastrointestinal procedures and kidney stone management.
- Cardiology: Develops and manufactures devices for treating coronary artery disease, heart failure, and other cardiovascular conditions, including stents, catheters, and pacemakers.
- Neuromodulation: Offers devices for chronic pain management and neurological disorders, including spinal cord stimulation and deep brain stimulation systems.
Leadership and Structure
The CEO is Michael F. Mahoney. The company has a hierarchical structure with distinct business units and functional departments such as R&D, manufacturing, and sales.
Top Products and Market Share
Key Offerings
- Watchman FLX Left Atrial Appendage Closure Device: A device to reduce the risk of stroke in patients with non-valvular atrial fibrillation. Competitors include Abbott's Amulet and Medtronic's pending device. Market share is significant, with estimates suggesting Boston Scientific holds a leading position. Revenue is a major contributor to the Cardiology segment.
- Polarx Cryoablation System: Used for the treatment of atrial fibrillation. Competitors include Medtronic and Johnson & Johnson. Market share is growing, with increasing adoption in electrophysiology labs. Revenue contribution is increasing year over year.
- Vercise Genus Deep Brain Stimulation (DBS) System: Used for treatment of Parkinson's disease. Competitors include Medtronic and Abbott. Market share is smaller in Neuromodulation compared to competitors but is expanding. Revenue contribution is moderate to low.
Market Dynamics
Industry Overview
The medical device industry is characterized by innovation, strict regulatory oversight, and increasing demand due to an aging population and rising healthcare expenditures. Significant growth is expected in minimally invasive procedures and remote monitoring technologies.
Positioning
Boston Scientific Corp is a major player in the medical device industry, known for its innovation in less-invasive technologies. Its competitive advantages include a broad product portfolio, strong R&D capabilities, and established relationships with healthcare providers.
Total Addressable Market (TAM)
The total addressable market for medical devices is estimated to be hundreds of billions of dollars. Boston Scientific Corp is well-positioned to capture a significant portion of this market due to its diversified product offerings and global presence.
Upturn SWOT Analysis
Strengths
- Strong brand reputation
- Diversified product portfolio
- Extensive distribution network
- Robust R&D capabilities
- Experience in Acquisitions
Weaknesses
- High debt levels
- Dependence on key products
- Vulnerability to regulatory changes
- Integration risk from acquisitions
- Pricing pressure
Opportunities
- Expansion into emerging markets
- Development of new technologies (e.g., robotics, AI)
- Acquisition of complementary businesses
- Increased demand for minimally invasive procedures
- Strategic partnership
Threats
- Intense competition
- Pricing pressure from healthcare providers
- Product liability lawsuits
- Economic downturns
- Technological Disruptions
Competitors and Market Share
Key Competitors
- Medtronic (MDT)
- Abbott (ABT)
- Johnson & Johnson (JNJ)
Competitive Landscape
Boston Scientific excels in specific markets through innovative products and strong customer relationships, but faces intense competition from larger and more diversified companies.
Major Acquisitions
Devoro Medical
- Year: 2021
- Acquisition Price (USD millions): 330
- Strategic Rationale: Expanded Boston Scientific's venous thrombus management portfolio.
Farapulse
- Year: 2021
- Acquisition Price (USD millions): 295
- Strategic Rationale: Pulsed Field Ablation (PFA) system for atrial fibrillation treatment.
Growth Trajectory and Initiatives
Historical Growth: Boston Scientific Corp has achieved consistent revenue growth through product innovation and strategic acquisitions.
Future Projections: Analysts project continued revenue growth in the mid-single digits, driven by new product launches and market expansion.
Recent Initiatives: Recent initiatives include the acquisition of Devoro Medical, the launch of new products in the Cardiology and Neuromodulation segments, and investments in digital health technologies.
Summary
Boston Scientific is a strong player in the medical device industry, particularly in less-invasive technologies. Its diverse product portfolio and continuous innovation drive revenue growth. The company's debt levels and competitive pressures need to be monitored closely. Acquisitions play a key role in their strategy, yet effective integration is essential for sustained growth. Expansion into new markets and technological advancements present further opportunities.
Similar Companies
ABT
Abbott Laboratories
ABT
Abbott Laboratories
EW
Edwards Lifesciences Corp
EW
Edwards Lifesciences Corp
JNJ
Johnson & Johnson
JNJ
Johnson & Johnson
MDT
Medtronic PLC
MDT
Medtronic PLC
SYK
Stryker Corporation
SYK
Stryker Corporation
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10K, 10Q)
- Analyst Reports (e.g., from major investment banks)
- Industry Publications (e.g., Medical Device and Diagnostic Industry)
- Company Press Releases
- Market Research Reports
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Market share data are estimates and may vary. Investment decisions should be based on independent research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Boston Scientific Corp
Exchange NYSE | Headquaters Marlborough, MA, United States | ||
IPO Launch date 1992-05-18 | Chairman, President & CEO Mr. Michael F. Mahoney | ||
Sector Healthcare | Industry Medical Devices | Full time employees 53000 | Website https://www.bostonscientific.com |
Full time employees 53000 | Website https://www.bostonscientific.com | ||
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates in two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention portfolios; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, proprietary programming software, radiofrequency ablation, indirect decompression systems, and intraosseous nerve ablation and deep brain stimulation systems. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat, and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.